Status:

COMPLETED

Characterization of Serial Magnetic Resonance Spectroscopy Imaging in Patients With Malignant Glioma Undergoing Radiotherapy

Lead Sponsor:

AHS Cancer Control Alberta

Conditions:

Malignant Glioma

Eligibility:

All Genders

18+ years

Brief Summary

Malignant glioma is the most common primary brain tumor in adults. Despite aggressive therapy, less than 40% of these patients are expected to live beyond 5 years. The radiologic imaging of these tumo...

Detailed Description

Background: Malignant glioma is the most common primary brain tumor in adults. Despite aggressive therapy, less than 40% of these patients are expected to live beyond 5 years. External beam radiother...

Eligibility Criteria

Inclusion

  • Patients must be older than 18 years of age.
  • Patients must have histologically proven malignant glioma of the brain.
  • Patients must have bi-directionally measurable enhancing residual disease by T1 weighted image.
  • Patients must be willing to undergo high dose radiotherapy to the brain for the treatment of their glial tumor.
  • Patients must be willing and able to comply with all study requirements.
  • The patient or legally authorized representative must fully understand all elements of informed consent, and sign the consent document.

Exclusion

  • History of previous RT to the head and neck region.
  • History of lupus, scleroderma or RT hypersensitivity.
  • Co-existing medical condition precluding radiotherapy.
  • Psychiatric conditions precluding informed consent.
  • Medical or psychiatric conditions precluding MR studies (eg. pacemaker, aneurysm clips, neuro stimulator, cochlear implant, severe claustrophobia/anxiety).

Key Trial Info

Start Date :

May 1 2005

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

June 1 2015

Estimated Enrollment :

49 Patients enrolled

Trial Details

Trial ID

NCT00125697

Start Date

May 1 2005

End Date

June 1 2015

Last Update

July 18 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cross Cancer Institute

Edmonton, Alberta, Canada, T6G 1Z2